Novel variations and loss of heterozygosity of BRCA2 identified in a dog with mammary tumors

Yasunaga Yoshikawa Laboratory of Cytology and Histology, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.

Search for other papers by Yasunaga Yoshikawa in
Current site
Google Scholar
PubMed
Close
 DVM
,
Masami Morimatsu Laboratory of Animal Experiment for Disease Model, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan.

Search for other papers by Masami Morimatsu in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Kazuhiko Ochiai Innovation Center Okayama for Nanobio-targeted Therapy, Okayama University, Okayama 700-8558, Japan.

Search for other papers by Kazuhiko Ochiai in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Masashi Nagano Department of Theriogenology, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.

Search for other papers by Masashi Nagano in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Yukiko Tomioka Laboratory of Animal Experiment for Disease Model, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan.

Search for other papers by Yukiko Tomioka in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Nobuo Sasaki Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.

Search for other papers by Nobuo Sasaki in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Kazuyoshi Hashizume Laboratory of Veterinary Physiology, Department of Veterinary Medicine, Iwate University, Morioka 020-8550, Japan.

Search for other papers by Kazuyoshi Hashizume in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Toshihiko Iwanaga Laboratory of Cytology and Histology, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.

Search for other papers by Toshihiko Iwanaga in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To establish novel polymorphic markers for analysis of loss of heterozygosity (LOH), so as to study the possible involvement of BRCA2 in mammary tumors obtained from dogs.

Sample Population—Blood samples, mammary gland specimens, or mammary tumors from 3 tumor-bearing dogs and 10 tumor-free dogs.

Procedures—Nucleotide sequence analysis was performed with a DNA autosequencer. Loss of heterozygosity analysis was performed for markers established in the present study. The expression level of canine BRCA2 was quantified by real-time PCR analysis.

Results—3 novel microsatellite markers with high heterozygosity rates (> 50%) were established, and the previously reported marker for canine BRCA2 gene locus was improved. These markers were used for the analysis of DNA from formalin-fixed and paraffin-embedded samples. By use of these markers, LOH in canine BRCA2 was identified as a result of recombination. In mammary tumor DNA that corresponded to the LOH-positive dog, the level of canine BRCA2 expression was decreased compared with that of nonneoplastic mammary gland tissue; the open reading frame contained 4 missense variations, 1 insertion variation, and 1 silent variation, some of which were localized to functional domains.

Conclusions and Clinical Relevance—3 novel polymorphic markers were developed for LOH analysis of canine BRCA2 and identified a dog with LOH with some variations in the functional domains. These markers could be useful for assessing the relevance of BRCA2 variation in mammary tumors of dogs.

Abstract

Objective—To establish novel polymorphic markers for analysis of loss of heterozygosity (LOH), so as to study the possible involvement of BRCA2 in mammary tumors obtained from dogs.

Sample Population—Blood samples, mammary gland specimens, or mammary tumors from 3 tumor-bearing dogs and 10 tumor-free dogs.

Procedures—Nucleotide sequence analysis was performed with a DNA autosequencer. Loss of heterozygosity analysis was performed for markers established in the present study. The expression level of canine BRCA2 was quantified by real-time PCR analysis.

Results—3 novel microsatellite markers with high heterozygosity rates (> 50%) were established, and the previously reported marker for canine BRCA2 gene locus was improved. These markers were used for the analysis of DNA from formalin-fixed and paraffin-embedded samples. By use of these markers, LOH in canine BRCA2 was identified as a result of recombination. In mammary tumor DNA that corresponded to the LOH-positive dog, the level of canine BRCA2 expression was decreased compared with that of nonneoplastic mammary gland tissue; the open reading frame contained 4 missense variations, 1 insertion variation, and 1 silent variation, some of which were localized to functional domains.

Conclusions and Clinical Relevance—3 novel polymorphic markers were developed for LOH analysis of canine BRCA2 and identified a dog with LOH with some variations in the functional domains. These markers could be useful for assessing the relevance of BRCA2 variation in mammary tumors of dogs.

All Time Past Year Past 30 Days
Abstract Views 35 0 0
Full Text Views 6854 6410 95
PDF Downloads 185 68 8
Advertisement